Lung Cancers Active Not Recruiting Phase 3 Trials for Nivolumab (DB09035)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03195491A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in AsiaTreatment
NCT02538666An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyTreatment
NCT02481830Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerTreatment
NCT02713867A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 WeeksTreatment